小柯机器人

美国基因泰克肿瘤学生物标志物开发Barzin Y. Nabet、Namrata S. Patil合作发现瘤内浆细胞可预测非小细胞肺癌 (NSCLC) PD-L1 阻断的疗效。该研究于2022年2月24日发表于国际一流学术期刊《癌细胞》杂志上。

通过对来自两项大型随机临床试验的接受 PD-L1 抑制剂atezolizumab 或化疗的患者的 891 例 NSCLC 肿瘤进行转录组学分析，他们发现 B 细胞与延长总体生存 (OS)与 PD-L1 阻断显著相关，独立于 CD8+ T 细胞信号。然后，他们从单细胞 RNA 测序 (RNA-seq) 数据中得出与 NSCLC 中存在的主要 B 细胞亚群相对应的基因特征。

重要的是，他们发现浆细胞特征增加可以预测接受 atezolizumab 治疗的患者的OS，但不能预测化疗的OS。B 细胞和浆细胞也与三级淋巴结构和有组织的淋巴聚集体的存在有关。他们的结果表明 B 细胞和浆细胞对 PD-L1 阻断在 NSCLC 中的功效具有重要贡献。

据了解，程序性细胞死亡-1 (PD-1/PD-L1) 信号轴抑制剂被批准用于治疗NSCLC患者，因为它们具有显著的OS益处。

附：英文原文

Title: Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Author: Namrata S. Patil, Barzin Y. Nabet, Sren Müller, Hartmut Koeppen, Wei Zou, Jennifer Giltnane, Amelia Au-Yeung, Shyam Srivats, Jason H. Cheng, Chikara Takahashi, Patricia E. de Almeida, Avantika S. Chitre, Jane L. Grogan, Linda Rangell, Sangeeta Jayakar, Maureen Peterson, Allison W. Hsia, William E. O’Gorman, Marcus Ballinger, Romain Banchereau, David S. Shames

Issue&Volume: 2022-02-24

Abstract: Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approvedto treat non-small cell lung cancer (NSCLC) patients, based on their significant overallsurvival (OS) benefit. Using transcriptomic analysis of 891 NSCLC tumors from patientstreated with either the PD-L1 inhibitor atezolizumab or chemotherapy from two largerandomized clinical trials, we find a significant B cell association with extendedOS with PD-L1 blockade, independent of CD8+ T cell signals. We then derive gene signatures corresponding to the dominant B cellsubsets present in NSCLC from single-cell RNA sequencing (RNA-seq) data. Importantly,we find increased plasma cell signatures to be predictive of OS in patients treatedwith atezolizumab, but not chemotherapy. B and plasma cells are also associated withthe presence of tertiary lymphoid structures and organized lymphoid aggregates. Ourresults suggest an important contribution of B and plasma cells to the efficacy ofPD-L1 blockade in NSCLC.

DOI: 10.1016/j.ccell.2022.02.002

Source: https://www.cell.com/cancer-cell/fulltext/S1535-6108(22)00035-6

Cancer Cell：《癌细胞》，创刊于2002年。隶属于细胞出版社，最新IF：38.585
官方网址：https://www.cell.com/cancer-cell/home
投稿链接：https://www.editorialmanager.com/cancer-cell/default.aspx